Protara Therapeutics, Inc.
TARA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001359931
No open-market purchases or sales by Protara Therapeutics, Inc. insiders were filed in the last 90 days; 119 institutions reported holding it in 13F filings for Q2 2026, worth $176.0M in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Protara Therapeutics, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 29
- −1 vs. Q4 2022
- Shares held
- 5.50M
- +25.0K (+0.5%) vs. Q4 2022
- Total value
- $16.9M
- +$2.21M (+15.0%) vs. Q4 2022
- New holders
- 2
- 5 more added
- Sold out
- 3
- 6 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TARA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 119 | $176.0M |
| Q1 2026 | 114 | $237.4M |
| Q4 2025 | 105 | $212.3M |
| Q3 2025 | 81 | $114.0M |
| Q2 2025 | 76 | $90.1M |
| Q1 2025 | 59 | $123.8M |
| Q4 2024 | 60 | $156.6M |
| Q3 2024 | 35 | $19.1M |
| Q2 2024 | 38 | $22.2M |
| Q1 2024 | 34 | $18.3M |
| Q4 2023 | 30 | $8.17M |
| Q3 2023 | 31 | $8.55M |
| Q2 2023 | 29 | $12.3M |
| Q1 2023 | 29 | $16.9M |
| Q4 2022 | 30 | $14.7M |
| Q3 2022 | 31 | $16.7M |
| Q2 2022 | 33 | $18.4M |
| Q1 2022 | 35 | $33.2M |
| Q4 2021 | 38 | $46.5M |
| Q3 2021 | 36 | $43.7M |
| Q2 2021 | 40 | $69.3M |
| Q1 2021 | 50 | $134.0M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Protara Therapeutics, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 100 | $0 | 0.00% | +100 | New |
| Advisor Group Holdings, Inc. | 100 | $313 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 560 | $1.75K | 0.00% | +1+0.2% | Added |
| UBS Group AG | 971 | $3.04K | 0.00% | −1,329−57.8% | Reduced |
| Acadian Asset Management LLC | 6,314 | $19.0K | 0.00% | 00.0% | Unchanged |
| LPL Financial LLC | 10,025 | $31.4K | 0.00% | +10,025 | New |
| Dimensional Fund Advisors LP | 16,834 | $52.2K | 0.00% | 00.0% | Unchanged |
| Assenagon Asset Management S.A. | 17,336 | $54.3K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 17,907 | $56.0K | 0.00% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 18,864 | $59.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 20,587 | $64.4K | 0.00% | +568+2.8% | Added |
| Millennium Management LLC | 26,321 | $82.0K | 0.00% | −3,305−11.2% | Reduced |
| State Street Corp | 30,900 | $95.8K | 0.00% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 31,618 | $99.0K | 0.00% | −15,600−33.0% | Reduced |
| Two Sigma Investments, LP | 35,745 | $111.9K | 0.00% | −10,402−22.5% | Reduced |
| BlackRock Inc. | 37,092 | $116.1K | 0.00% | +732+2.0% | Added |
| Citadel Advisors LLC | 46,187 | $143.2K | 0.00% | +31,339+211.1% | Added |
| Morgan Stanley | 58,364 | $182.7K | 0.00% | +58,339+233,356.0% | Added |
| Renaissance Technologies LLC | 58,906 | $184.0K | 0.00% | −8,094−12.1% | Reduced |
| Bridgeway Capital Management, LLC | 64,000 | $198.4K | 0.01% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 83,420 | $258.6K | 0.00% | 00.0% | Unchanged |
| Privium Fund Management (UK) Ltd | 119,730 | $401.1K | 0.32% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 188,664 | $584.9K | 0.24% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 199,671 | $625.0K | 0.00% | 00.0% | Unchanged |
| Boxer Capital, LLC | 209,227 | $655.0K | 0.03% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 290,051 | $907.9K | 0.03% | 00.0% | Unchanged |
| Vanguard Group Inc | 427,612 | $1.34M | 0.00% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 793,558 | $2.48M | 0.05% | −37,083−4.5% | Reduced |
| Opaleye Management Inc. | 2,692,594 | $8.08M | 2.42% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −124−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −22−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −133−100.0% | Sold out |